Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019

Summary

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 11 October 2019

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 11 October 2019

   Introduced

   Introduced in House

   Source: IntroReferral

3. 11 October 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 14 October 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 11 October 2019 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 11 October 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 11 October 2019

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 11 October 2019

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. DeFazio, Peter A. [D-OR-4] · D · Sponsor
• Rep. Doggett, Lloyd [D-TX-37] · D · Cosponsor
• Rep. Khanna, Ro [D-CA-17] · D · Cosponsor
• Sen. Welch, Peter [D-VT] · D · Cosponsor
• Rep. Pocan, Mark [D-WI-2] · D · Cosponsor
• Rep. Schakowsky, Janice D. [D-IL-9] · D · Cosponsor
• Rep. DeLauro, Rosa L. [D-CT-3] · D · Cosponsor
• Rep. Grijalva, Raúl M. [D-AZ-7] · D · Cosponsor
• Rep. Cohen, Steve [D-TN-9] · D · Cosponsor
• Rep. Kaptur, Marcy [D-OH-9] · D · Cosponsor
• Rep. Pingree, Chellie [D-ME-1] · D · Cosponsor
• Rep. García, Jesús G. "Chuy" [D-IL-4] · D · Cosponsor
• · hsif00 · Standing

Related records

• related to ← To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.